[The following is an automated notice from the StartEngine team].

Hello!

As you might know, PhorMed has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in PhorMed be on the lookout for an email that describes more about the disbursement process.

This campaign will continue to accept investments until its indicated closing date.

Thanks for funding the future.

-StartEngine

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, PhorMed has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in PhorMed be on the lookout for an email that describes more about the disbursement process.

This campaign will continue to accept investments until its indicated closing date.

Thanks for funding the future.

-StartEngine

PhorMed

OFFERING MAX INCREASED TO $5 MILLION

PhorMed is excited to announce that after working through the SEC requirements we are now successfully back on track with our crowdfunding efforts. We have increased our raise to $5 Million! We would like to thank all our existing investors and all those who continued to invest on the waitlist.

To all our Waitlist investors, please make sure you respond to StartEngine emails to confirm your purchase of shares, in order to ensure that you secure your investment.

Thank you for your support,

Stuart Greene

VP of Marketing and Business Development

PhorMed

MCCOY MORETZ, M.D.

It is with great sadness that we announce the passing of “Dr. Mac,” McCoy Moritz, M.D., who died unexpectedly after a brief illness. The entire PhorMed family mourns his loss and extends our deepest sympathies to his family. Dr. Moritz was a brilliant and compassionate physician and medical researcher who brought great dedication to his stewardship of PhorMed as its Chief Executive Officer (CEO) and Chief Medical Officer (CMO).

Ben Chang, President, Chief Financial Officer (CFO), Chairman and Co-Founder, will step in as interim CEO and continues to oversee the day-to-day management of the company. A graduate of East Carolina University with a degree in Economics and International Finance, Ben has over 26 years of pharmaceutical and executive experience. He is also co-inventor of the PhorMed Anti-Virus/COVID-19 patent.

Dr. Sean O’Connell will step up from his seat on the PhorMed Scientific and Medical Advisory Board to serve as Chief Medical Officer (CMO). 

Dr. O’Connell received his Ph.D. in Immunology and Molecular Biology from Rutgers University. As a post-doctoral fellow at Rutgers University School of Pharmacy, he worked closely with Dr. Richard Chang, conducting a variety of studies on the action of TPA on promyeloid bone marrow cells. 

A seasoned healthcare professional with over 65 peer-reviewed publications, Dr. O’Connell has steered numerous venture capital, pharmaceutical, biotechnology, medical device and tissue processing companies through pre-clinical and clinical development, commercial opportunity assessment, all the way through product and marketing development. Dr. O’Connell met Dr. Moritz as part of a team of surgeons working at Chang’an Hospital in Xi’an, China. Together they developed an autologous stem cell therapy to treat a variety of deleterious skin conditions.

“Dr. Mac contributed immensely to the establishment and growth of PhorMed,” said Ben Chang. “His knowledge, drive, and friendship will be profoundly missed. On behalf of the entire PhorMed family, I would like to reiterate our commitment to seeing his visions realized.”

[The following is an automated notice from the StartEngine team].

Hello! Recently, a change was made to the PhorMed offering. Here's an excerpt describing the specifics of the change:

PhorMed provided audited financials and increased their maximum funding goal.

When live offerings undergo changes like these on StartEngine, the SEC requires that certain investments be reconfirmed. If your investment requires reconfirmation, you will be contacted by StartEngine via email with further instructions.

[The following is an automated notice from the StartEngine team].

Hello! Recently, a change was made to the PhorMed offering. Here's an excerpt describing the specifics of the change:

PhorMed updated the Directors and Officers, provided updated financials, and extended the duration of their campaign.

When live offerings undergo changes like these on StartEngine, the SEC requires that certain investments be reconfirmed. If your investment requires reconfirmation, you will be contacted by StartEngine via email with further instructions.

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, PhorMed has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in PhorMed be on the lookout for an email that describes more about the disbursement process.

This campaign will continue to accept investments until its indicated closing date.

Thanks for funding the future.

-StartEngine

[The following is an automated notice from the StartEngine team].

Hello! Recently, a change was made to the PhorMed offering. Here's an excerpt describing the specifics of the change:

Phormed is extending its campaign.

When live offerings undergo changes like these on StartEngine, the SEC requires that certain investments be reconfirmed. If your investment requires reconfirmation, you will be contacted by StartEngine via email with further instructions.

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, PhorMed has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in PhorMed be on the lookout for an email that describes more about the disbursement process.

This campaign will continue to accept investments until its indicated closing date.

Thanks for funding the future.

-StartEngine

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, PhorMed has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in PhorMed be on the lookout for an email that describes more about the disbursement process.

This campaign will continue to accept investments until its indicated closing date.

Thanks for funding the future.

-StartEngine

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, PhorMed has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in PhorMed be on the lookout for an email that describes more about the disbursement process.

This campaign will continue to accept investments until its indicated closing date.

Thanks for funding the future.

-StartEngine

 PhorMed

Absorption Systems Collaboration Announcement

PhorMed will be entering into a collaboration agreement with Absorption Systems, a laboratory that will be conducting pre-clinical research in the COVID-19 and Parkinson’s disease areas. This partnership is also a key component in the company’s NIH grant application process. “We are very fortunate to solidify this partnership with a staff that has such extensive knowledgeable in the pre-clinical arena and a facility that is so well equipped, fulfilling many of our needs” said Ben Chang, Chairman of the Board. 

About Absorption Systems

Absorption Systems, founded in 1996, assists pharmaceutical, biotechnology and medical device companies in identifying and overcoming ADMET (Absorption, Distribution, Metabolism, Excretion and Toxicity) barriers in the development of drugs, biologics and medical devices. The company's mission is to continually develop innovative research tools that can be used to accurately predict human outcomes or to explain unanticipated human outcomes when they occur. IDAS2, a novel in vitro test system for simultaneous screening of drug absorption and dissolution, exemplifies Absorption Systems' commitment to innovation and is soon to be an industry standard for formulation assessment. Absorption Systems, with facilities near Philadelphia, PA, in San Diego, CA, and in Medford, MA, serves customers throughout the world. For information on the company's comprehensive contract services, applied research programs, and proprietary test systems, please visit www.absorption.com.

[The following is an automated notice from the StartEngine team].

Hello! Recently, a change was made to the PhorMed offering. Here's an excerpt describing the specifics of the change:

PhorMed increased the length of their offering.

When live offerings undergo changes like these on StartEngine, the SEC requires that certain investments be reconfirmed. If your investment requires reconfirmation, you will be contacted by StartEngine via email with further instructions.

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, PhorMed has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in PhorMed be on the lookout for an email that describes more about the disbursement process.

This campaign will continue to accept investments until its indicated closing date.

Thanks for funding the future.

-StartEngine

PhorMed

EMORY University Collaboration Announcement

PhorMed Inc (“PhorMed” or the “Company”) has entered into an agreement with Atlanta-based academic research leader Emory University for assistance in developing the Company’s proprietary drug for Parkinson’s disease. 

“Emory’s experts, with their extensive knowledge in Parkinson’s disease, will be a great addition to the PhorMed team and we look forward to a long and successful collaboration” said Dr. McCoy Moretz, the Chief Executive Officer of the company. 

About Emory University:

Emory University

LAST UPDATED: JANUARY 29, 2020

Founded in 1836, Emory University is a national center for teaching, research, and service, awarding more than 4,921 undergraduate and graduate degrees annually. It is recognized by U.S. News & World Report as one of the top 25 universities in the US (ranked 21st in the 2019 report). In 1966 the University’s Board of Trustees integrated all of Emory’s health components into the Robert W. Woodruff Health Sciences Center. The Woodruff Health Sciences Center joins those components of Emory University concerned with patient care, education of health professionals, research affecting health and illness, and policies for prevention and treatment of disease. Its components include schools of medicine, nursing, and public health; Yerkes National Primate Research Center; Winship Cancer Institute; Emory Global Health Institute, and Emory Healthcare, the most comprehensive health system in Georgia. 

See http://www.emory.edu/home/about/factsfigures/index.html

Funded Research at Emory

Researchers at Emory University received $734 million from external funding agencies in fiscal year 2018, marking a 17 percent increase over the previous year, with such funding having increased more than 50 percent over the past 10 years. Federal agencies awarded $440.8 million, or more than 60 percent of the total, led by the National Institutes of Health, with $359.2 million in awards. NIH funding represented nearly 82 percent of total federal dollars awarded to Emory.

See second article in http://whsc.emory.edu/publications/hs-update-archive/11-2018.html

And https://news.emory.edu/features/2018/11/record-research-funding/index.html

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, PhorMed has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in PhorMed be on the lookout for an email that describes more about the disbursement process.

This campaign will continue to accept investments until its indicated closing date.

Thanks for funding the future.

-StartEngine

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, PhorMed has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in PhorMed be on the lookout for an email that describes more about the disbursement process.

This campaign will continue to accept investments until its indicated closing date.

Thanks for funding the future.

-StartEngine

[The following is an automated notice from the StartEngine team].

Hello! Recently, a change was made to the PhorMed offering. Here's an excerpt describing the specifics of the change:

Extended length of campaign.

When live offerings undergo changes like these on StartEngine, the SEC requires that certain investments be reconfirmed. If your investment requires reconfirmation, you will be contacted by StartEngine via email with further instructions.

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, PhorMed has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in PhorMed be on the lookout for an email that describes more about the disbursement process.

This campaign will continue to accept investments until its indicated closing date.

Thanks for funding the future.

-StartEngine

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, PhorMed has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in PhorMed be on the lookout for an email that describes more about the disbursement process.

This campaign will continue to accept investments until its indicated closing date.

Thanks for funding the future.

-StartEngine

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, PhorMed has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in PhorMed be on the lookout for an email that describes more about the disbursement process.

This campaign will continue to accept investments until its indicated closing date.

Thanks for funding the future.

-StartEngine

[The following is an automated notice from the StartEngine team].

Hello! Recently, a change was made to the PhorMed offering. Here's an excerpt describing the specifics of the change:

Extended length of campaign.

When live offerings undergo changes like these on StartEngine, the SEC requires that certain investments be reconfirmed. If your investment requires reconfirmation, you will be contacted by StartEngine via email with further instructions.

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, PhorMed has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in PhorMed be on the lookout for an email that describes more about the disbursement process.

This campaign will continue to accept investments until its indicated closing date.

Thanks for funding the future.

-StartEngine

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, PhorMed has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in PhorMed be on the lookout for an email that describes more about the disbursement process.

This campaign will continue to accept investments until its indicated closing date.

Thanks for funding the future.

-StartEngine

Our drug, RP-323, is a gene repair therapy that has the ability to repair damaged or mutated cells.

Please watch our video to learn more. 

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, PhorMed has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in PhorMed be on the lookout for an email that describes more about the disbursement process.

This campaign will continue to accept investments until its indicated closing date.

Thanks for funding the future.

-StartEngine

[The following is an automated notice from the StartEngine team].

Hello! Recently, a change was made to the PhorMed offering. Here's an excerpt describing the specifics of the change:

Extended length of campaign.

When live offerings undergo changes like these on StartEngine, the SEC requires that certain investments be reconfirmed. If your investment requires reconfirmation, you will be contacted by StartEngine via email with further instructions.

Our filing status is now current with the Securities and Exchange Commission. On May 4, 2020 we filed our C-AR, annual report, fulfilling our reporting obligations for securities sold pursuant to Regulation CF.

We will be unable to meet our April 29, 2020, annual report filing requirements for securities sold pursuant to Regulation CF as a result of the officer in charge had contracted COVID-19 and was unavailable to meet the deadline.. As such, we intend to rely on the temporary relief being provided by the Securities and Exchange Commission. We will continue to use our best efforts to comply with our ongoing reporting obligations.

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, PhorMed has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in PhorMed be on the lookout for an email that describes more about the disbursement process.

This campaign will continue to accept investments until its indicated closing date.

Thanks for funding the future.

-StartEngine

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, PhorMed has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in PhorMed be on the lookout for an email that describes more about the disbursement process.

This campaign will continue to accept investments until its indicated closing date.

Thanks for funding the future.

-StartEngine

How It Works

With PhorMed’s expanded pipeline adding “Anti-Virus and Suppression of Pulmonary Inflammation” to help fight COVID-19, PhorMed’s drug RP-323 will help people with compromised immune systems.   PhorMed’s goal is to assist the elderly and those with pre-existing conditions by boosting their immune systems and preventing fatalities among those patients who have contracted COVID-19.   

RP-323 has the ability to activate the body’s defense system boosting White Blood Cells (WBC) which include T-cell, B-cells, interferon, cytokines, antibodies and more. In clinical trials over 90% of patients using RP-323 had elevation of WBC, which is the primary need of people fighting COVID-19.  

Thank you all and be well,

McCoy Moretz, M.D., CEO

PhorMed Expands Pipeline

• On March 24, 2020 PhorMed entered into an assignment agreement to acquire a new indication for ANTI-VIRUS AND SUPPRESSION OF PULMONARY INFLAMMATION using RP-323.
• PhorMed will collaborate with Professor Richard L. Chang to develop this Coronavirus COVID-19 fighting indication.
• Professor Chang will share all data, existing protocols and FDA communications related to battling viruses.
• A safety profile has already been submitted to the FDA.
• This new collaboration expands our pipeline and ability to apply our platform technology to an additional indication.
• PhorMed remains committed to patients suffering from diseases with little or no treatment options.

Thank you all and be well,

McCoy Moretz, M.D., CEO

[The following is an automated notice from the StartEngine team].

Hello! Recently, a change was made to the PhorMed offering. Here's an excerpt describing the specifics of the change:

Extended length of campaign.

When live offerings undergo changes like these on StartEngine, the SEC requires that certain investments be reconfirmed. If your investment requires reconfirmation, you will be contacted by StartEngine via email with further instructions.

Introduction

Although I have communicated with several of our investors on the Comment Board, I wanted to formally introduce myself. My name is Stuart Greene and I am the Director of Marketing and Business Development for PhorMed. It has been my pleasure to be welcomed as a part of the PhorMed family, and see the dedication to creating new treatment options for patients suffering from disorders where the traditional treatments like radiation and chemotherapy can be devastating in themselves, or where no real treatments are available in cases like Parkinson’s disease.

Clinical Site Announcement

I am excited to let you know that we are in final stages and have completed the legal review of our agreement with our clinical site. They are now working on the SOW and once that is completed, we will execute the agreement and will then announce their partnership. So please stay tuned for that announcement.

Campaign Status

Since the start of the campaign we were able to complete the initial raise of $107k, and subsequently increased our raise to the current $1.07m goal. Our campaign is ending in 5 days and we want to sincerely thank all of our investors and extend our gratitude for helping us to address these unmet medical needs. We look forward to continuing our efforts to offer hope for patients suffering from our targeted indications.

Thank you all and be well,

Stuart Greene

Director of Marketing and Business Development

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, PhorMed has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in PhorMed be on the lookout for an email that describes more about the disbursement process.

This campaign will continue to accept investments until its indicated closing date.

Thanks for funding the future.

-StartEngine

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, PhorMed has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in PhorMed be on the lookout for an email that describes more about the disbursement process.

This campaign will continue to accept investments until its indicated closing date.

Thanks for funding the future.

-StartEngine

[The following is an automated notice from the StartEngine team].

Hello! Recently, a change was made to the PhorMed offering. Here's an excerpt describing the specifics of the change:

Phormed has increased its max funding goal and provided updated financials with an independent CPA review.

When live offerings undergo changes like these on StartEngine, the SEC requires that certain investments be reconfirmed. If your investment requires reconfirmation, you will be contacted by StartEngine via email with further instructions.

[The following is an automated notice from the StartEngine team].

Hello!

As you might know, PhorMed has exceeded its minimum funding goal. When a company reaches its minimum on StartEngine, it's about to begin withdrawing funds. If you invested in PhorMed be on the lookout for an email that describes more about the disbursement process.

This campaign will continue to accept investments until its indicated closing date.

Thanks for funding the future.

-StartEngine